Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in EOC after prior PARP inhibitor
NCT05489926Phase 2Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pamiparib in epithelial ovarian cancer (EOC), sponsored by Zhejiang Cancer Hospital. Started Aug 2022; status: active, not recruiting.
02
Drugs
pamiparib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05489926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489926.